A Phase 3 interventional study of Denosumab 70 mg/mL and Zoledronic acid 4 mg in Fractures, Bone, sponsored by GlaxoSmithKline. Completed at 25 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Fractures, Bone with a site in China — 4 open to participants now, 5 under way, none of them phase 3. Fractures, Bone · China.
Among the 23 studies in Fractures, Bone with a site in China, this one is the 2nd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2013, is the only one in phase 3, and was the 4th registered.
725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.
Browse Fractures, Bone studies →4 of the 23 studies in Fractures, Bone with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–65
Capital Medical University · Sites in China
Ages 18–100
Hebei Medical University Third Hospital · Sites in China
Ages 17+ · Healthy volunteers
Peking Union Medical College Hospital · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 72 Fractures, Bone studies recruiting now, 36 (50%) set no upper age limit and 22 (31%) stop at 75 or younger; 17 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 4
First in 2003; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 487 is above the median of 80 across 458 interventional studies indexed under Fractures, Bone.
Median enrollment 86 across the 20 interventional studies, 800 across the 3 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 23 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 3 studies filed under Fractures, Bone — fewer than ten, so there is no comparison to draw.
1 of the studies in Fractures, Bone with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07063797Peking Union Medical College HospitalStudy on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Fractures, Bone with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, double-dummy study designed to provide bridging data in an Asian population to Amgen's studies of denosumab in subjects with bone metastases from solid tumors. The study is designed to provide data to a large global dataset of phase-III studies including breast cancer, prostate cancer, and all solid tumors, plus multiple myeloma, to support the regulatory approval for marketing and patient access to denosumab for the prevention of SREs in Chinese subjects with bone metastases from solid tumors. The primary objective of this study is to evaluate and compare the percent change from baseline to Week 13 in the bone marker urinary amino-terminal cross-linking telopeptide of type I collagen (uNTx) corrected for urine creatinine (uNTx/uCr) in subjects treated with denosumab to those treated with zoledronic acid. The study is designed to test the superiority of denosumab over zoledronic acid.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over \>=15 minutes once every 4 weeks.
Biological: Denosumab 70 mg/mL · Drug: Placebo IV · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement
Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
Drug: Zoledronic acid 4 mg · Drug: Placebo SC · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement
Drug page: Denosumab
Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr)
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment (trt). uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Primary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Asian ancestry with bone metastases from solid tumors. BL value is the most recent, non-missing value prior to or on the 1st study trt dose date. Chg from BL is the value at Wk13 minus BL value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
Time frame: Baseline (BL) and Week (Wk) 13
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants.
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Chinese ancestry with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
Time frame: Baseline and Week 13
Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer.
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in breast cancer par. with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
Time frame: Baseline and Week 13
Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13.
Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Indicated visit minus Baseline value. Percent change from Baseline is the change from Baseline divided by Baseline value multiplied by 100.
Time frame: Baseline and Week 13
Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (Non-fatal Serious Adverse Events and Fatal Serious Adverse Events)
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, non-fatal SAEs, fatal SAEs have been presented.
Time frame: From start of IP through the Study Phase (49 weeks post-dose) (assessed up to 73 weeks)
Number of Participants With Worst-case (WC) On-therapy Increase in the Indicated Clinical Chemistry Parameters From Baseline Grade to the Indicated Grade.
Clinical chemistry parameters were measured at the Screening and Weeks 2, 5, 9, 13, 25, 37, and 53 visits. Clinical chemistry parameters measured on-study included albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium (Ca), creatinine, magnesium, and phosphorous (P) inorganic. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) was used for grading. Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: Baseline and up to last study-related visit (up to 53 weeks)
Number of Participants With Worst-case On-therapy Increase in the Indicated Hematology Parameters From Baseline Grade to the Indicated Grade.
Hematology parameters included hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell (WBC) count. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
Time frame: Baseline and up to last study-related visit (up to 53 weeks)
Number of Participants With Confirmed Anti-denosumab Antibody Formation at Day 1, Week 25 and Week 53.
Anti-denosumab antibody formation was assessed at Day 1, Week 25 and Week 53. Binding antibody assay was used to assess number of participants with anti-denosumab antibody.
Time frame: Day 1, Week 25 and Week 53
Serum Concentration of Denosumab on Day 1, at Week 2, Week 5, Week 9, Week 13, Week 17, Week 19, Week 21, Week 25 and Week 49
Blood samples were drawn on study Day 1, pre-dose; 4 hours, 24 hours, and at Week 2 (168 hours); then pre-dose at Week 5, Week 9, Week 13, Week 17, Week 19 (no dose), Week 21, Week 25, and Week 49.
Time frame: Samples were collected at pre-dose (Day 1); 4 hours, 24 hours, 168 hours post-dose; pre-dose at Week 5, Week 9, Week 13, Week 17; Week 19 (at 336 hours); pre-dose at Week 21, Week 25, Week 49
The study consisted of three phases: Screening period , 49-week Double-blind treatment period and Follow-up period. The total participation time in the study was approximately 77 weeks.
| Milestone | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Started | 326 | 159 |
| Completed | 175 | 75 |
| Not completed | 151 | 84 |
| Withdrew: Adverse event | 27 | 8 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Physician decision | 13 | 4 |
| Withdrew: Withdrawal by subject | 79 | 55 |
| Withdrew: Death due to disease progression | 25 | 12 |
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment (trt). uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Primary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Asian ancestry with bone metastases from solid tumors. BL value is the most recent, non-missing value prior to or on the 1st study trt dose date. Chg from BL is the value at Wk13 minus BL value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
| Percent change | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Percent Change (Chg) From Baseline (BL) to Week (Wk)13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) | -81.9 (-83.1 to -80.6) | -75.2 (-77.6 to -72.5) |
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in par. of Chinese ancestry with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
| Percent change | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Chinese Participants. | -82.2 (-83.4 to -80.8) | -75.6 (-78.0 to -72.9) |
uNTx/uCr is the bone turnover marker correlated with the presence and extent of metastases, and the prognosis and response to bone targeted treatment. uNTx/uCr was expressed in nanomoles bone collagen equivalent per millimole (nM BCE/mM). Secondary objective: to compare the effect of denosumab with that of zoledronic acid on % chg from BL in uNTx/uCr at Wk 13 in breast cancer par. with bone metastases from solid tumors. Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Week 13 minus Baseline value. Percent chg from BL is the chg from BL / BL value \* 100. For missing Wk 13 observations, the last post-BL value was carried forward to obtain the Wk 13 value.
| Percent change | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Percentage Change From Baseline to Week 13 in Urinary Amino-terminal Cross-linking Telopeptide of Type I Collagen of Type I Collagen Corrected for Urine Creatinine (uNTx/uCr) in Participants With Advanced Breast Cancer. | -80.9 (-82.7 to -78.9) | -72.4 (-76.1 to -68.2) |
Baseline value is the most recent, non-missing value prior to or on the first study treatment dose date. Change from Baseline is the value at Indicated visit minus Baseline value. Percent change from Baseline is the change from Baseline divided by Baseline value multiplied by 100.
| Percent change | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Percent Change From Baseline in the Serum Bone-specific Alkaline Phosphatase (s-BALP) at Week 13. | -36.8 (-96.2 to 93.8) | -30.3 (-91.7 to 345.9) |
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or other events that may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcome listed above, liver injury and impaired liver function and grade 4 laboratory abnormalities. Number of participants with any AEs, non-fatal SAEs, fatal SAEs have been presented.
| Participants | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Any AEs | 291 | 145 |
| Any SAEs | 46 | 14 |
| Any Fatal SAEs | 25 | 7 |
| Any Non-Fatal SAEs | 25 | 7 |
Clinical chemistry parameters were measured at the Screening and Weeks 2, 5, 9, 13, 25, 37, and 53 visits. Clinical chemistry parameters measured on-study included albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, calcium (Ca), creatinine, magnesium, and phosphorous (P) inorganic. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) was used for grading. Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Albumin (hyperalbuminemia), any grade, n=324, 156 | 0 | 0 |
| Albumin (hyperalbuminemia), WC G3, n=324, 156 | 0 | 0 |
| Albumin (hyperalbuminemia), WC G4, n=324, 156 | 0 | 0 |
| Albumin (hypoalbuminemia), any grade, n=324, 156 | 45 | 26 |
| Albumin (hypoalbuminemia), WC G3, n=324, 156 | 1 | 0 |
| Albumin (hypoalbuminemia), WC G4, n=324, 156 | 0 | 0 |
| ALP, any grade, n=324, 156 | 67 | 31 |
| ALP, WC G3, n=324, 156 | 7 | 2 |
| ALP, WC G4, n=324, 156 | 0 | 0 |
| ALT, any grade, n=324, 156 | 137 | 59 |
| ALT, WC G3, n=324, 156 | 7 | 4 |
| ALT, WC G4, n=324, 156 | 0 | 0 |
| AST, any grade, n=323, 155 | 117 | 61 |
| AST, WC G3, n=323, 155 | 7 | 4 |
| AST, WC G4, n=323, 155 | 0 | 0 |
| Total Bilirubin, any grade, n=324, 155 | 34 | 16 |
| Total Bilirubin, WC G3, n=324, 155 | 2 | 0 |
| Total Bilirubin, WC G4, n=324, 155 | 2 | 1 |
| Calcium (hypercalcemia), any grade, n=324, 156 | 4 | 3 |
| Calcium (hypercalcemia), WC G3, n=324, 156 | 0 | 0 |
| Calcium (hypercalcemia), WC G4, n=324, 156 | 0 | 1 |
| Calcium (hypocalcemia), any grade, n=324,156 | 78 | 28 |
| Calcium (hypocalcemia), WC G3, n=324, 156 | 5 | 0 |
| Calcium (hypocalcemia), WC G4, n=324, 156 | 1 | 0 |
| Creatinine, any grade, n=324, 156 | 16 | 13 |
| Creatinine, WC G3, n=324, 156 | 1 | 0 |
| Creatinine, WC G4, n=324, 156 | 0 | 0 |
| Magnesium (hypermagnesemia), any grade, n=324, 156 | 4 | 0 |
| Magnesium (hypermagnesemia), WC G3, n=324, 156 | 2 | 0 |
| Magnesium (hypermagnesemia), WC G4, n=324, 156 | 0 | 0 |
| Magnesium (hypomagnesemia), any grade, n=324, 156 | 8 | 2 |
| Magnesium (hypomagnesemia), WC G3, n=324, 156 | 0 | 0 |
| Magnesium (hypomagnesemia), WC G4, n=324, 156 | 0 | 0 |
| P,inorganic(hyperphosphatemia),any grade,n=323,156 | 0 | 0 |
| P, inorganic (hyperphosphatemia),WC G3, n=323, 156 | 0 | 0 |
| P, inorganic (hyperphosphatemia),WC G4, n=323, 156 | 0 | 0 |
| P,inorganic(hypophosphatemia),any grade,n=323, 156 | 124 | 35 |
| P, inorganic (hypophosphatemia),WC G3, n=323, 156 | 35 | 9 |
| P, inorganic (hypophosphatemia), WC G4, n=323, 156 | 1 | 0 |
Hematology parameters included hemoglobin, lymphocytes, platelet count, total neutrophils, white blood cell (WBC) count. All reported values are of participants with worst-case on-therapy increase to the specified grade: Any increase, that is, worst-case increase to grade 1, 2, 3, or 4 (any grade); worst-case increase to grade 3 (WC G3); and worst-case increase to grade 4 (WC G4). Participants with missing Baseline grade were assumed to have a Baseline grade of 0. The worst-case during the on-therapy period was determined taking into account both scheduled and unscheduled assessments.
| Participants | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Hemoglobin, any grade, n=316, 147 | 139 | 69 |
| Hemoglobin, WC G3, n=316, 147 | 24 | 11 |
| Hemoglobin, WC G4, n=316, 147 | 0 | 0 |
| Lymphocyte count decreased, any grade, n=315, 147 | 77 | 47 |
| Lymphocyte count decreased, WC G3, n=315, 147 | 21 | 14 |
| Lymphocyte count decreased, WC G4, n=315, 147 | 1 | 1 |
| Lymphocyte count increased, any grade, n=315, 147 | 2 | 2 |
| Lymphocyte count increased, WC G3, n=315, 147 | 0 | 0 |
| Lymphocyte count increased, WC G4, n=315, 147 | 0 | 0 |
| Platelet count, any grade, n=314, 144 | 77 | 48 |
| Platelet count, WC G3, n=314, 144 | 2 | 5 |
| Platelet count, WC G4, n=314, 144 | 2 | 1 |
| Total neutrophils, any grade, n=315, 147 | 124 | 58 |
| Total neutrophils, WC G3, n=315, 147 | 40 | 19 |
| Total neutrophils, WC G4, n=315, 147 | 12 | 8 |
| WBC count, any grade, n=315, 147 | 138 | 78 |
| WBC count, WC G3, n=315, 147 | 25 | 19 |
| WBC count, WC G4, n=315, 147 | 2 | 1 |
Anti-denosumab antibody formation was assessed at Day 1, Week 25 and Week 53. Binding antibody assay was used to assess number of participants with anti-denosumab antibody.
| Participants | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Day 1, n = 326, 158 | 0 | 0 |
| Week 25, n = 256, 115 | 0 | 0 |
| Week 53, n = 180, 76 | 0 | 0 |
Blood samples were drawn on study Day 1, pre-dose; 4 hours, 24 hours, and at Week 2 (168 hours); then pre-dose at Week 5, Week 9, Week 13, Week 17, Week 19 (no dose), Week 21, Week 25, and Week 49.
| micrograms per milliliter (µg/mL) | Denosumab 120 mg |
|---|---|
| Day 1, Pre-dose, n=26 | 0 (0 to 0) |
| Day 1, 4 hours post-dose, n=26 | 777.1 (574.2 to 1051.6) |
| Day 1, 24 hours post-dose, n=26 | 5521.6 (4744.2 to 6426.3) |
| Week 2, 168 hours post-dose, n=26 | 11701.1 (10554.0 to 12973.0) |
| Week 5, Pre-dose, n=25 | 8658.1 (7631.1 to 9823.3) |
| Week 9, Pre-dose, n=25 | 12086.4 (10284.9 to 14203.4) |
| Week 13, Pre-dose, n=25 | 14867.5 (12515.5 to 17661.6) |
| Week 17, Pre-dose, n=24 | 16543.3 (13871.8 to 19729.2) |
| Week 19, 336 hours, n=22 | 20802.4 (16280.7 to 26579.9) |
| Week 21, Predose, n=21 | 14508.0 (10907.0 to 19297.9) |
| Week 25, Predose, n=22 | 16619.0 (13354.9 to 20681.0) |
| Week 49, Predose, n=19 | 20029.2 (16282.7 to 24637.9) |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of IP through the Study Phase (49 weeks post-dose) (assessed up to 73 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 120 mg | — | 46/326 (14.1%) | 268/326 (82.2%) |
| Zoledronic Acid 4 mg | — | 14/159 (8.8%) | 136/159 (85.5%) |
| Event | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/326 | 2/159 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/326 | 2/159 |
| Hepatic function abnormalHepatobiliary disorders | 0/326 | 2/159 |
| PneumoniaInfections and infestations | 3/326 | 1/159 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/326 | 0/159 |
| Disease progressionGeneral disorders | 3/326 | 0/159 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/326 | 0/159 |
| DiarrhoeaGastrointestinal disorders | 1/326 | 1/159 |
| Urinary tract infectionInfections and infestations | 1/326 | 1/159 |
| Acute myocardial infarctionCardiac disorders | 0/326 | 1/159 |
| Event | Denosumab 120 mg | Zoledronic Acid 4 mg |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 81/326 | 39/159 |
| White blood cell count decreasedInvestigations | 68/326 | 38/159 |
| PyrexiaGeneral disorders | 41/326 | 32/159 |
| Decreased appetiteMetabolism and nutrition disorders | 61/326 | 32/159 |
| Neutrophil count decreasedInvestigations | 55/326 | 30/159 |
| Alanine aminotransferase increasedInvestigations | 56/326 | 28/159 |
| NauseaGastrointestinal disorders | 57/326 | 23/159 |
| LeukopeniaBlood and lymphatic system disorders | 55/326 | 27/159 |
| NeutropeniaBlood and lymphatic system disorders | 54/326 | 25/159 |
| Aspartate aminotransferase increasedInvestigations | 49/326 | 26/159 |
| Age, Continuous(Years) | Denosumab 120 mg | Zoledronic Acid 4 mg | Total |
|---|---|---|---|
| Mean | 54.0 ± 11.36 | 53.6 ± 11.45 | 53.9 ± 11.38 |
| Gender(Participants) | Denosumab 120 mg | Zoledronic Acid 4 mg | Total |
|---|---|---|---|
| Female | 222 | 105 | 327 |
| Male | 104 | 54 | 158 |
| Race/Ethnicity, Customized(Participants) | Denosumab 120 mg | Zoledronic Acid 4 mg | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 312 | 158 | 470 |
| Asian - South East Asian Heritage | 14 | 1 | 15 |
The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Denosumab · Zoledronic Acid